Jazz Pharmaceuticals (NASDAQ: JAZZ) EVP Patil sells 55,600 shares

Rhea-AI Filing Summary

Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported a mix of stock option exercises, share sales, and equity awards. She exercised multiple incentive and non-qualified stock options into ordinary shares and sold a total of 55,600 ordinary shares in open-market transactions at weighted average prices generally around $190–$193 per share. Patil also acquired 10,079 restricted stock units granted under the 2011 Equity Incentive Plan, which vest in equal annual installments over four years starting on March 5, 2026. Following these transactions, she directly owns 58,818 ordinary shares of Jazz Pharmaceuticals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patil Neena M

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/26/2026		M		20,125	A	$113.1	73,464	D
Ordinary Shares	02/26/2026		S		16,602	D	$192.5271(1)	56,862	D
Ordinary Shares	02/26/2026		M		875	A	$113.1	57,737	D
Ordinary Shares	02/26/2026		S		875	D	$192.0651(2)	56,862	D
Ordinary Shares	02/26/2026		M		27,084	A	$137.12	83,946	D
Ordinary Shares	02/26/2026		S		15,555	D	$190.2801(3)	68,391	D
Ordinary Shares	02/26/2026		M		2,916	A	$137.12	71,307	D
Ordinary Shares	02/26/2026		S		2,916	D	$189.8117(4)	68,391	D
Ordinary Shares	02/26/2026		A(5)		10,079	A	$0.0	78,470	D
Ordinary Shares	02/26/2026		S		11,529	D	$191.6455(6)	66,941	D
Ordinary Shares	02/26/2026		S		3,523	D	$193.5831(7)	63,418	D
Ordinary Shares	02/26/2026		S		1,061	D	$190.0035(8)	62,357	D
Ordinary Shares	02/26/2026		S		549	D	$190.7963(9)	61,808	D
Ordinary Shares	02/26/2026		S		1,784	D	$191.8789(10)	60,024	D
Ordinary Shares	02/26/2026		S		1,009	D	$192.7915(11)	59,015	D
Ordinary Shares	02/26/2026		S		197	D	$193.5982(12)	58,818	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)	$113.1	02/26/2026		M			875	(13)	02/26/2030	Ordinary Shares	875	$0.0	0	D
Incentive Stock Option (right to buy)	$137.12	02/26/2026		M			2,916	(14)	08/07/2029	Ordinary Shares	2,916	$0.0	0	D
Non-Qualified Stock Option (right to buy)	$113.1	02/26/2026		M			20,125	(13)	02/26/2030	Ordinary Shares	20,125	$0.0	0	D
Non-Qualified Stock Option (right to buy)	$137.12	02/26/2026		M			27,084	(14)	08/07/2029	Ordinary Shares	27,084	$0.0	0	D

Explanation of Responses:

1. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.1100 to $193.0100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.0600 to $192.1100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.9150 to $190.9000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

4. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $189.7300 to $189.9150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

5. These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

6. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.3200 to $192.0600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

7. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.2900 to $193.8400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

8. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.395 to $190.3700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

9. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.4100 to $191.2150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

10. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.4750 to $192.4300. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

11. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $192.4600 to $193.4500. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

12. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $193.5300 to $193.6700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

13. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

14. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.

	By: /s/Paz Dizon, as attorney in fact For: Neena Patil	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Jazz Pharmaceuticals (JAZZ) report for Neena M. Patil?

Neena M. Patil reported exercising stock options, selling 55,600 ordinary shares, and receiving 10,079 restricted stock units. All transactions occurred on February 26, 2026, reflecting both liquidity sales and new equity incentives tied to her role at Jazz Pharmaceuticals.

How many Jazz Pharmaceuticals (JAZZ) shares did Neena Patil sell and at what prices?

Neena Patil sold 55,600 ordinary shares of Jazz Pharmaceuticals in multiple open-market transactions. Footnotes state these sales occurred in numerous trades at weighted average prices generally between $189.39 and $193.84 per share, with detailed trade breakdowns available upon request.

What new equity awards did Neena Patil receive from Jazz Pharmaceuticals (JAZZ)?

Neena Patil received 10,079 restricted stock units representing rights to receive one ordinary share each upon vesting. These units were granted under Jazz’s 2011 Equity Incentive Plan and vest annually over four years starting on March 5, 2026, aligning compensation with long-term company performance.

What is Neena Patil’s direct share ownership in Jazz Pharmaceuticals (JAZZ) after these transactions?

After completing the reported option exercises, share sales, and restricted stock unit grant, Neena Patil directly owns 58,818 ordinary shares of Jazz Pharmaceuticals. This figure reflects her updated direct holdings as of the end of the transactions on February 26, 2026.

Did Neena Patil exercise stock options in the latest Jazz Pharmaceuticals (JAZZ) Form 4?

Yes. The Form 4 shows Neena Patil exercising multiple incentive and non-qualified stock options into ordinary shares. These exercises were reported with transaction code “M,” which indicates the exercise or conversion of derivative securities into Jazz Pharmaceuticals ordinary shares.

How do Neena Patil’s restricted stock units in Jazz Pharmaceuticals (JAZZ) vest?

Neena Patil’s 10,079 restricted stock units vest in equal annual installments over four years starting on March 5, 2026. One quarter vests on the first anniversary, with the remaining units vesting in equal annual installments over the following three years, subject to plan terms.